Início › Leucemia Linfocítica Crônica › Colorado
Ensaios clínicos de Leucemia Linfocítica Crônica em Colorado
17 estudos para Leucemia Linfocítica Crônica estão buscando participantes em locais em Colorado.
Cidades em Colorado
Texto oficial do estudo (Inglês)
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- Kaiser Permanente-Franklin, Denver
- Kaiser Permanente-Rock Creek, Lafayette
- Kaiser Permanente-Lone Tree, Lone Tree
RecrutandoFase 3
Idades 65 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT07321652Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Rocky Mountain Regional VA Medical Center, Aurora
- UCHealth University of Colorado Hospital, Aurora
- Penrose-Saint Francis Healthcare, Colorado Springs
- e mais 15
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
Idades de 40 a 75 · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT05334069Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Grand Valley Oncology, Grand Junction
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 30 de set. de 2026 · NCT04269902A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Rocky Mountain Cancer Centers (Williams) Usor, Aurora
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT06943872A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Uchealth North, Fort Collins
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT05006716A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
- Rocky Mountain Cancer Centers (Williams) Usor, Aurora
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT07277231A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
- Rocky Mountain Cancer Centers (Williams) Usor, Aurora
- Intermountain Health Lutheran Hospital Cancer Center of Colorado, Golden
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT06846671A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Saint Joseph Hospital ( Site 0026), Denver
- Lutheran Medical Center ( Site 0027), Golden
- Intermountain Health St. Mary's Regional Hospital ( Site 0025), Grand Junction
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 24 de set. de 2026 · NCT06136559Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- CBCI, Colorado Blood Cancer Institute, Denver
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 21 de set. de 2026 · NCT07648264A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- Colorado Blood Institute, Denver
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 17 de set. de 2026 · NCT07221500Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
- Rocky Mountain Cancer Centers, Aurora
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 28 de ago. de 2026 · NCT07520006Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Colorado Blood Cancer Institute, Denver
RecrutandoFase 1/2
Idades de 13 a 90 · Todos os sexos · Atualizado em 6 de ago. de 2026 · NCT06533579A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Colorado Blood Cancer Institute, Denver
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 2 de jul. de 2026 · NCT05131022A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Rocky Mountain Cancer Center, Aurora
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 19 de mai. de 2026 · NCT06588478A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Rocky Mountain Cancer Centers - Aurora /ID# 267549, Aurora
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 9 de abr. de 2026 · NCT06428019A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- Sarah Cannon Research Institute at Colorado Blood Cancer Institute, Denver
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 20 de mar. de 2026 · NCT04830137A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- Colorado Blood Cancer Institute, Denver
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2025 · NCT05780034Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.